DFTX net incomeQ2 2026-$158.99M
DFTX net income was -$158.99M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$42.74M a year earlier. For the full fiscal 2025 it was -$183.79M, compared with -$108.68M in fiscal 2024.
Definium Therapeutics Inc. (DFTX) financials
For the twelve months ended Jun 30, 2026, Definium Therapeutics Inc. reported -$353.79M of net income.
- Net income, TTM
- -$353.79M
- EPS, diluted, TTM
- -$3.36
- Cash
- $655.27M
- Total debt
- $36.47M
- Market cap
- $4.47B
FY2020FY2025
DFTX revenue and earnings growth
DFTX EPSQ2 2026-$1.44
DFTX diluted EPS was -$1.44 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.50 a year earlier. For the full fiscal 2025 it was -$2.06, compared with -$1.54 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $117.67M | $65.30M | $52.12M | $36.17M | $34.79M | $18.63M |
| Selling, general and admin | $48.64M | $38.62M | $41.74M | $30.16M | $59.06M | $14.40M |
| Operating income | -$166.31M | -$103.92M | -$93.87M | -$66.33M | -$93.85M | -$33.03M |
| Interest expense | $5.48M | $2.28M | $920.0K | - | - | - |
| Pre-tax income | -$183.79M | -$108.68M | -$95.73M | -$56.80M | -$94.19M | -$33.94M |
| Income tax | $0 | - | - | - | -$1.16M | - |
| Net income | -$183.79M | -$108.68M | -$95.73M | -$56.80M | -$93.04M | -$33.94M |
| EPS, basic | -$2.06 | -$1.54 | -$2.44 | -$1.84 | -$3.40 | -$0.13 |
| EPS, diluted | -$2.06 | -$1.54 | -$2.44 | -$1.84 | -$3.40 | -$0.13 |
| Diluted shares | 89.3M | 70.5M | 39.2M | 30.9M | 27.4M | 266.2M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $257.84M | $273.74M | $99.70M | $142.14M | $133.54M | $80.09M |
| Short-term investments | $153.76M | $0 | - | - | - | - |
| Current assets | $419.32M | $281.62M | $103.87M | $146.06M | $137.22M | $81.52M |
| Goodwill | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $0 |
| Total assets | $440.10M | $302.15M | $124.54M | $169.99M | $164.00M | $81.52M |
| Current liabilities | $66.70M | $38.85M | $32.25M | $17.89M | $10.41M | $3.01M |
| Long-term debt | $40.58M | $21.85M | $14.13M | - | - | - |
| Total debt | $40.58M | $21.85M | $14.13M | - | - | - |
| Total liabilities | $107.77M | $60.70M | $46.41M | $19.08M | $12.34M | $5.65M |
| Shareholders' equity | $332.33M | $241.45M | $78.13M | $150.92M | $151.66M | $75.87M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$131.56M | -$79.13M | -$64.36M | -$50.14M | -$45.82M | -$23.60M |
| Investing cash flow | -$151.61M | $0 | - | - | -$297.0K | - |
| Financing cash flow | $267.27M | $253.20M | $21.85M | $59.05M | $98.82M | $96.70M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Return on equity | -55.3% | -45.0% | -122.5% | -37.6% | -61.3% | -44.7% |
| Return on assets | -41.8% | -36.0% | -76.9% | -33.4% | -56.7% | -41.6% |
| Current ratio | 6.29 | 7.25 | 3.22 | 8.16 | 13.18 | 27.10 |
| Debt to equity | 0.12 | 0.09 | 0.18 | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $48.66M | $41.48M | $33.52M | $30.98M | $29.81M | $23.36M | $21.76M | $17.19M | $14.64M | $11.71M | $11.55M | $13.20M |
| Selling, general and admin | $26.41M | $17.74M | $14.06M | $14.69M | $11.09M | $8.80M | $10.70M | $7.60M | $9.81M | $10.50M | $10.66M | $8.41M |
| Operating income | -$75.08M | -$59.22M | -$47.58M | -$45.67M | -$40.90M | -$32.16M | -$32.46M | -$24.79M | -$24.46M | -$22.20M | -$22.20M | -$21.62M |
| Interest expense | $1.23M | $1.25M | $1.27M | $1.27M | $2.34M | $602.0K | $656.0K | $727.0K | $466.0K | $434.0K | $439.0K | $328.0K |
| Net income | -$158.99M | -$77.10M | -$50.44M | -$67.27M | -$42.74M | -$23.35M | -$34.74M | -$13.68M | -$5.85M | -$54.40M | -$23.86M | -$17.92M |
| EPS, basic | -$1.44 | -$0.71 | -$0.51 | -$0.78 | -$0.50 | -$0.27 | - | -$0.18 | -$0.08 | -$1.14 | -$0.58 | -$0.45 |
| EPS, diluted | -$1.44 | -$0.71 | -$0.43 | -$0.78 | -$0.50 | -$0.35 | - | -$0.27 | -$0.26 | -$1.14 | -$0.58 | -$0.45 |
| Diluted shares | 110.7M | 108.8M | - | 85.9M | 85.3M | 87.1M | - | 80.2M | 75.3M | 47.9M | - | 39.7M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $655.27M | $262.52M | $257.84M | $19.96M | $33.39M | $82.85M | $273.74M | $295.28M | $243.13M | $252.33M | $99.70M | $117.70M |
| Short-term investments | $428.61M | $110.90M | $153.76M | $189.11M | $149.60M | $129.59M | $0 | - | - | - | - | - |
| Current assets | $1.09B | $380.56M | $419.32M | $215.85M | $189.14M | $221.70M | $281.62M | $299.36M | $247.69M | $255.47M | $103.87M | $120.09M |
| Goodwill | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M |
| Total assets | $1.11B | $401.29M | $440.10M | $236.92M | $265.09M | $275.32M | $302.15M | $319.77M | $268.14M | $275.53M | $124.54M | $141.55M |
| Current liabilities | $157.20M | $81.11M | $66.70M | $65.42M | $37.96M | $30.48M | $38.85M | $33.27M | $41.85M | $65.27M | $32.25M | $31.15M |
| Long-term debt | $36.47M | $40.77M | $40.58M | $40.38M | $41.19M | $22.04M | $21.85M | $24.31M | $24.25M | $14.19M | $14.13M | $14.07M |
| Total debt | $36.47M | $40.77M | $40.58M | $40.38M | $41.19M | $22.04M | $21.85M | $24.31M | $24.25M | $14.19M | $14.13M | $14.07M |
| Total liabilities | $194.22M | $122.44M | $107.77M | $106.32M | $79.69M | $52.52M | $60.70M | $57.58M | $66.10M | $79.47M | $46.41M | $45.57M |
| Shareholders' equity | $918.68M | $278.85M | $332.33M | $130.60M | $185.40M | $222.81M | $241.45M | $262.19M | $202.05M | $196.06M | $78.13M | $95.98M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$52.78M | -$42.63M | -$42.98M | -$29.57M | -$29.60M | -$29.42M | -$25.35M | -$17.19M | -$19.99M | -$16.60M | -$20.56M | -$16.63M |
| Investing cash flow | -$316.74M | $42.00M | $34.98M | $15.41M | -$39.54M | -$162.46M | $0 | $0 | $0 | $0 | - | - |
| Financing cash flow | $762.27M | $5.31M | $245.87M | $749.0K | $19.65M | $1.00M | $3.81M | $69.35M | $10.79M | $169.25M | $2.59M | $17.40M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 6.95 | 4.69 | 6.29 | 3.30 | 4.98 | 7.27 | 7.25 | 9.00 | 5.92 | 3.91 | 3.22 | 3.85 |
| Debt to equity | 0.04 | 0.15 | 0.12 | 0.31 | 0.22 | 0.10 | 0.09 | 0.09 | 0.12 | 0.07 | 0.18 | 0.15 |
Source: XBRL data Definium Therapeutics Inc. files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
DFTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| DFTX | - | - | -$353.79M | - | $4.47B |
| PM | $43.14B | +7.9% | $10.71B | 24.8% | $308.43B |
| BTI | £25.61B | -1.0% | £7.76B | 30.3% | $131.54B |
| MO | $23.52B | +0.5% | $8.12B | 34.5% | $126.62B |
| RGC | - | - | -$11.70M | - | $2.61B |
| TRLV | $1.08B | -9.1% | -$445.60M | -41.2% | $2.23B |
| RLX | CN¥3.96B | +44.0% | CN¥921.87M | 23.3% | $1.97B |
| CRON | $271.85M | +54.3% | $63.36M | 23.3% | $1.33B |
| TLRY | $963.10M | +15.9% | -$164.22M | -17.1% | $430.8M |
DFTX FAQ
5 questionsIs DFTX profitable?
No. Definium Therapeutics Inc. reported a net loss of $353.79M for the twelve months ended Jun 30, 2026.How much cash and debt does DFTX have?
Definium Therapeutics Inc. reported $655.27M in cash and cash equivalents and $36.47M of debt on its most recent balance sheet in SEC filings.What is DFTX earnings per share?
Diluted earnings per share were -$3.36 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did DFTX last report financial results?
The latest statements here come from Definium Therapeutics Inc.'s 10-Q filed on Aug 6, 2026, covering the period ended Jun 30, 2026.Where does this DFTX financial data come from?
Quantisnow builds these statements from the structured XBRL data Definium Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.